The European Commission has granted market authorization to Sanofi for its insulin aspart biosimilar, making it the first approved biosimilar to NovoRapid for the region.
Sanofi has received marketing authorization for its insulin aspart biosimilar (Insulin aspart Sanofi) from the European Commission, becoming the first insulin aspart biosimilar to be approved in Europe.
Market authorization was granted on June 25 and Sanofi announced it on July 3.
“With Insulin aspart Sanofi, we will serve people with diabetes in a diverse range of age groups. This reflects our continued commitment to individualization of care for people with diabetes,” Alan Divanovic, MD, vice president of medical affairs at Sanofi, told Pharmacy Business.
The biosimilar references Novo Nordisk's NovoRapid and was approved for blood sugar control in adults, adolescents, and children aged 1 and older who have type 1 or type 2 diabetes.
The European Commission’s decision comes after the European Medicines Agency’s Committee for Human Medical Products issued a positive recommendation for approval in May 2020.
The approval was based on data from a clinical development project that involved more than 600 adult patients with type 1 or type 2 diabetes.
Sanofi investigators presented the study results from 3 late-breaking clinical trials at the American Diabetes Association 79th Scientific Sessions in June 2019, showing that Insulin aspart Sanofi was comparable to the reference product in pharmacokinetics, pharmacodynamics, safety, and efficacy.
Sanofi’s Growing Insulin Portfolio
This is Sanofi’s third rapid-acting insulin analog to be approved by European regulators. Its insulin glulisine originator (Apidra) was approved in Europe in 2004, and its insulin lispro follow-on product (Admelog) received European approval in 2017.
“By providing all 3 rapid-acting insulin options in glulisine, lispro, and aspart, Sanofi is expanding the affordability and sustainability of insulin treatments, giving payers, physicians and patients more flexibility,” Divanovic said.
Admelog was approved by FDA in 2017 and launched on the US market in April 2018.
Sanofi also released positive phase 3 clinical results for Toujeo, its follow-on insulin glargine product (Lantus), in pediatric patients in November 2019.
Sanofi is the maker of Lantus, an insulin glargine blockbuster product that is currently facing intense biosimilar competition in Europe and was the first insulin product to have a biosimilar approved there.
In December 2019, Sanofi announced that it would end its research and development efforts on diabetes and cardiovascular drugs in order to focus more on cancer immunotherapies and other biologics, but said that it will continue with its insulin business.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.